跳转至内容
Merck
CN
  • Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study.

Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study.

Cancer research (2014-10-23)
Sajin Bae, Cornelia M Ulrich, Marian L Neuhouser, Olga Malysheva, Lynn B Bailey, Liren Xiao, Elissa C Brown, Kara L Cushing-Haugen, Yingye Zheng, Ting-Yuan David Cheng, Joshua W Miller, Ralph Green, Dorothy S Lane, Shirley A A Beresford, Marie A Caudill
摘要

Few studies have examined associations between plasma choline metabolites and risk of colorectal cancer. Therefore, we investigated associations between plasma biomarkers of choline metabolism [choline, betaine, dimethylglycine, and trimethylamine N-oxide (TMAO)] and colorectal cancer risk among postmenopausal women in a case-control study nested within the Women's Health Initiative Observational Study. We selected 835 matched case-control pairs, and cases were further stratified by tumor site (proximal, distal, or rectal) and stage (local/regional or metastatic). Colorectal cancer was assessed by self-report and confirmed by medical records over the mean of 5.2 years of follow-up. Baseline plasma choline metabolites were measured by LC/MS-MS. In multivariable-adjusted conditional logistic regression models, plasma choline tended to be positively associated with rectal cancer risk [OR (95% confidence interval, CI)(highest vs. lowest quartile) = 2.44 (0.93-6.40); P trend = 0.08], whereas plasma betaine was inversely associated with colorectal cancer overall [0.68 (0.47-0.99); P trend = 0.01] and with local/regional tumors [0.64 (0.42-0.99); P trend = 0.009]. Notably, the plasma betaine:choline ratio was inversely associated with colorectal cancer overall [0.56 (0.39-0.82); P trend = 0.004] as well as with proximal [0.66 (0.41-1.06); P trend = 0.049], rectal [0.27 (0.10-0.78); P trend = 0.02], and local/regional [0.50 (0.33-0.76); P trend = 0.001] tumors. Finally, plasma TMAO, an oxidative derivative of choline produced by intestinal bacteria, was positively associated with rectal cancer [3.38 (1.25-9.16); P trend = 0.02] and with overall colorectal cancer risk among women with lower (vs. higher) plasma vitamin B12 levels (P interaction = 0.003). Collectively, these data suggest that alterations in choline metabolism, which may arise early in disease development, may be associated with higher risk of colorectal cancer. The positive association between plasma TMAO and colorectal cancer risk is consistent with an involvement of the gut microbiome in colorectal cancer pathogenesis.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氯化胆碱, ≥98%
Sigma-Aldrich
甜菜碱 溶液, 5 M, PCR Reagent
Sigma-Aldrich
维生素 B 12, ≥98%
Supelco
维生素B12, pharmaceutical secondary standard, certified reference material
Sigma-Aldrich
甜菜碱, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
吡哆醛5′-磷酸盐 水合物, ≥98%
Sigma-Aldrich
氯化胆碱, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Sigma-Aldrich
维生素 B 12, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
甜菜碱, ≥98% (perchloric acid titration)
Sigma-Aldrich
氯化胆碱, ≥99%
Sigma-Aldrich
三甲胺N-氧化物, 95%
Supelco
腈钴胺(维生素 B12), analytical standard
Sigma-Aldrich
甜菜碱 盐酸盐, ≥99%
Sigma-Aldrich
吡哆醛5′-磷酸盐 一水合物, ≥97.0% (NT)
Sigma-Aldrich
氯化胆碱, BioUltra, ≥99.0% (AT)
Sigma-Aldrich
吡哆醛5′-磷酸盐 水合物, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
氰钴胺, meets USP testing specifications
Supelco
氯化胆碱, Pharmaceutical Secondary Standard; Certified Reference Material
USP
氯化胆碱, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
氯化胆碱, Vetec, reagent grade, ≥98%
氰钴胺, British Pharmacopoeia (BP) Assay Standard
氰钴胺, European Pharmacopoeia (EP) Reference Standard